Maximum inhibition of phenylalanine hydroxylase activity in the liver (85 %) and in the kidney (50%) of suckling rats required the administration of over 9,pmol of p-chlorophenylalanine/lOg body weight. Despite the decrease in the total activity from 184 to 34 units per lOg body weight, the injection of as much as 26fmol of phenylalanine was required for its concentration in plasma to be still considerably elevated 12h later. In rats injected with p-chlorophenylalanine every 48h and with phenylalanine every 24h from 3 to 18 days of age, the hepatic and renal phenylalanine hydroxylase remained inhibited, whereas the activities of three other hepatic enzymes were unchanged. There was about 20 % inhibition of brain and body growth, but no interference with the developmental formation of several cerebral enzymes (four dehydrogenases, hexokinase and glutaminase) was detected. In the course of this prolonged treatment, the phenylalanine concentrations in plasma increased gradually; on day 2 and day 8 (measured 12h after the last injection) they were 800 and 1395 nmol/ml respectively; on day 15, 12 and 18h after the usual injection, the values were 2030 and 1030 respectively as opposed to the 96nmol in untreated rats. This degree of hyperphenylalaninaemia, persisting for 18h per day throughout a critical period of development, fulfils the primary criterion of a suitable animal model for phenylketonuria.
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Efforts to gain some understanding about the pathogenesis of mental retardation have led many investigators to focus on phenylketonuria, the inborn disease that manifests the closest association between a cognitive and a metabolic defect. Early attempts to reproduce in animals the condition of hyperphenylalaninaemia, characteristic of this human disease, consisted of maintaining rats on a high phenylalanine diet (e.g. Auerbach et al., 1958) . However, the efficiency of the normal organism to metabolize phenylalanine prevents it from accumulating in blood to the extent that it does in phenylketonuric subjects, owing to their inborn deficiency of hepatic phenylalanine hydroxylase (Knox, 1966) . There is also the practical difficulty of maintaining rats on experimental diets while they are still suckling. Another approach was made possible by the discovery of an agent, namely p-chlorophenylalanine, which inhibited the hepatic phenylalanine hydroxylase activity of adult rats (Koe & Weissman, 1966; Guroff, 1969) and thereby decreased the rate of elimination of ingested phenylalanine (Lipton et al., 1967) . In view of the increasing realization that the irreversible cerebral damage of phenylketonurics is caused by the high concentrations of circulating phenylalanine during early infancy (Knox, 1966) , studies in which suckling rats were treated withp-chlorophenylalanine Vol. 154 (and phenylalanine) are of particular interest. Several laboratories have reported promising results such as a learning deficit [tested by performance in a swimming maze (Watt & Martin, 1969) ], retarded accumulation of oleic acid in cerebral lipids (Foote & Tao, 1968) , and even behavioural symptoms akin to those in phenylketonuric subjects (Andersen & Guroff, 1972; Andersen et al., 1974) . However, these papers do not contain measurements of the concentration of phenylalanine in plasma, and it is therefore not clear whether the treatments induced sustained hyperphenylalaninaemia. Even the daily administration of phenylalanine plus p-chlorophenylalanine in the study of Andersen et al. (1974) may have been insufficient, since a report by Lipton et al. (1967) showed that, at least in adult p-chlorophenylalanine-treated rats, the concentrations of phenylalanine in plasma return to normal as early as 3 h after the administration of 12,umol of phenylalanine/lOg body wt. The extent of loss of phenylalanine hydroxylase activity was also uncertain, since the maximum effective dose of p-chlorophenylalanine in suckling rats has not been determined, nor was it known whether this agent inhibited the appreciable activity present in kidney (McGee et al., 1972a) .
The present study was based on the hypothesis, that a major, sustained elevation of the concentration ofphenylalanine in plasma is the primary criterion for the adequacy of an animal model system for phenylketonuria. We first determined the amount of pchlorophenylalanine required to cause maximum inhibition of the hepatic and renal phenylalanine hydroxylase activity in immature rats and then the amount of phenylalanine to be administered to cause a prolonged (at least 12h) and considerable increase in its concentration in plasma. The results indicate that such sustained elevations were unlikely to have occurred with the regimen used in the above studies reporting behavioural abnormalities.
Some of the observations made in the course of developing this animal model for phenylketonuria led to separate investigations of the mechanism of regulation of phenylalanine hydroxylase by pchlorophenylalanine, phenylalanine and cortisol. These results are described in the following paper (Greengard & DelValle, 1976) .
Experimental

Materials
Rats were of the albino CDF strain, maintained on Purina Chow diet fed ad libitum. The adult rats were 75-to 90-day-old males. p-Chlorophenylalanine (Aldrich Chemical Co., Milwaukee, WI, U.S.A.) was suspended at room temperature (24°C) in 0.9 % NaCl and sonicated to small particle size. This suspension was stirred, and 0.1-2 ml sucked into a syringe and injected immediately. L-Phenylalanine was dissolved in 0.9 % NaCl by heating.
Methods
Determinations of phenylalanine, tyrosine and p-chlorophenylalanine concentrations. Blood was collected in heparinized microhematocrit capillary tubes, centrifuged for 5min and the supernatant diluted with 4vol. of trichloroacetic acid (final concn. 0.3M). The precipitated proteins were left for 20min at room temperature, then sedimented in a clinical centrifuge for 20 min at maximum speed. Portions of the supernatant to be assayed with a Beckman 120C automatic amino acid analyser were diluted with a 0.2M-sodium citrate buffer, pH2.2, and applied to a column (69cmxO.9cm) of Beckman type PA-28 spherical resin at 55°C. The flow rate was 50mi/h for the elution buffer (0.2M-sodium citrate, pH4.25) and 25 ml/h for the ninhydrin solution, peaks corresponding to phenylalanine, tyrosine and p-chlorophenylalanine appeared at 128, 215 and 280min respectively. The concentrations (nmol) were then calculated from the areas under the peaks. The standard amino acid solution was purchased from Pierce Chemical Co., Rockford, IL, U.S.A. The phenylalanine concentration in plasma from animals that had not Teceived injections of p-chlorophenylalanine was also determined fluorimetrically (results not shown) by the method of McCaman & Robins (1962) , as modified by Faulkner (1965) , and were consistently found to be 15-20% higher than those obtained in the amino acid analyser.
Enzyme assays. The assay method for hepatic and renal phenylalanine hydroxylase activity was as described by Greengard & DelValle (1976) . Previously established methods were used for the assay of tyrosine aminotransferase (EC 2.6.1.5) (Lin et al., 1958) , soluble and mitochondrial aspartate aminotransferase (EC 2.6.1.1) (Herzfeld & Greengard, 1971 ) and the malate dehydrogenase (EC 1.1.1.37) (Ochoa, 1955) activities of liver extracts. The assay for glutaminase (EC 3.5.1.2) and succinate dehydrogenase (EC 1.3.99.1) activities in the particulate fraction of cerebral hemispheres (hereafter referred to as 'brain') were those of Huang (1974) and Laatsch et al. (1962) . The malate-NADPt dehydrogenase (EC 1.1.1.40) (Greengard & Jamdar, 1971) , glutamate dehydrogenase (EC 1.4.1.2) (MacDonnell & Greengard, 1974) , hexokinase (EC 2.7.1.1) (MacDonnell & Greengard, 1974) and lactate dehydrogenase (EC 1.1.1.27) (MacDonnell & Greengard, 1974) activities were determined in cerebral homogenates after standing for 30min at 0OC with Triton X-100 (final concn. 0.5 %). Enzyme activities are reported in units/ g fresh wt. of tissue; a unit is the amount of product formed/min at 25°C (nmol for phenylalanine hydroxylase and ,umol for all other enzymes).
Results
To determine the extent to which p-chlorophenylalanine can inhibit the phenylalanine hydroxylase activity of immature liver in vivo,-various amounts were injected into 6-day-old rats 24h before assay. Fig. I shows that at least 9pmol/lOg body wt. was required to cause 85 % inhibition and that one-half of this dose resulted in only 35% inhibition. In adult livers with a higher basal phenylalanine hydroxylase activity (McGee et al., 1972a) , the percentage inhibition caused by a maximally effective dose of pchlorophenylalanine was slightly higher than in immature rats (Table 1) . (As shown by the values in line 3, a simultaneous administration ofphenylalanine did not influence the degree of inhibition.) At both ages the activity remained minimal for at least 30h; the values at 48 h suggest that therecovery of hepatic phenylalanine hydroxylase activity may begin somewhat earlier in the immature than in the adult rats. McGee et al. (1972a) reported that kidney also. contains significant phenylalanine hydroxylase activity, which increases during early postnatal life. The purpose of the experiments of Table 2 was to determine the amounts ofp-chlorophenylalanine and phenylalanine that need to be injected into inumature rats to cause substantial, prolonged rises in the concentration of plasma phenylalanine. In 6-day-old rats, as in adult rats (Lipton et al., 1967) , some increase was seenafter an injection ofp-chlorophenylalanine alone. The administration ofp-chlorophenyl- alanine, together with 13 and 26,umol of phenylalanine/lOg 12h before assay, resulted in 480 and 841 nmol of phenylalanine/ml of plasma respectively. A second injection ofeither the lower or the higher dose of phenylalanine given 24h after thep-chlorophenylalanine was as effective as the first. As expected, p-chlorophenylalanine decreased the concentration of tyrosine in plasma; only with the higher dose of phenylalanine did it reach the plasma concentration of normal untreated rats (356nmoA/ml).
The last line ofTable 2 refers to rats injected with the same amounts of substrate and analogue that were used previously (Andersen & Guroff, 1972; Andersen et al., 1974) in the prolonged treatment of infant rats. After 12h the plasma concentration of phenylalanine was only 30% above normal, whereas that of tyrosine was very high. This can be explained by the small inhibition of the hepatic phenylalanine hydroxylase activity with 34umol of p-chlorophenylalanine/lOg body wt. (see Fig. 1 ).
Since the phenylalanine hydroxylase activities (Table 1 ) and the metabolism of injected phenylalanine (Table 2 ) remained inhibited for 48h after the administration of p-chlorophenylalanine, this agent was injected only every other day in the course of prolonged treatment. The first part of Table 3 illustrates the "results obtained with intraperitoneal injections given from day 3 to day 11 and day 15 of life. The concentration ofphenylalanine in plasma was still ten times above normal 18h after the last injection. At 12h, it was higher (2020nmol/ml) in the 15-day-old than in the 11-day-old group (l390nmol/ ml), but even in the latter it was higher than seen in the acute experinents (841 nmol/ml, see Table 2 ). where the 'rats received the same doses of p-chlorophenylalanine plus phenylalanine, but only once. This apparently gradual accumulation of phenylalanine in the course of chronic treat-ment is not due to afurther diminution of phenylalanine hydroxylase activity (cf. Tables 1 and 3 ). Repeated treatment with p-chlorophenylalanine alone also resulted in higher concen- (3) 12 (26) 12 (13) 36, 12 (13) 12 (26) 36, 12 (26) 12 (20) Phenylalanine p-Chlorophenylalanine (nmol/ml of plasma) (nmol/ml of plasma) 97±13 trations of plasma phenylalanine (and of p-chlorophenylalanine) than those expected from observations on rats given a single injection ofp-chlorophenylalanine (cf . Tables 2 and 3 ).
The ratio phenylalanine/tyrosine in the plasma of rats injected with p-chlorophenylalanine plus phenylalanine appears to be higher in the chronic (3-4, see Table 3 ) than in the acute experiments (about 2, see Table 2 ). More important, when the absolute concentration of phenylalanine in the plasma was 14-20 times above normal, that of tyrosine was elevated only 1.2 and 1.5 times (Table 3) .
The last line of Table 3 shows that repeated subcutaneous injections of p-chlorophenylalanine (at one-half the dose) and phenylalanine (usual dose) also gave the desired increase in concentrations of phenylalanine in plasma. The death rate in this group (10% or less by the age of 18 days) was lower than those in the upper part of Table 3 (about 50 %). Table 4 shows that prolonged treatment with p-chlorophenylalanine and phenylalanine resulted in 24, 21 and 17% decreases of body, brain and liver weights respectively. The treatment did not affect the hepatic concentration of three soluble enzymes and of the mitochondrial isoenzyme of aspartate aminotransferase. Ofthe cerebral enzymes studied, some are exclusively particulate (glutamate dehydrogenase, glutaminase and succinate dehydrogenase); the 1976 Greengard, unpublished work; MacDonnell & Greengard, 1974; Banik & Davison, 1969) . Table 4 shows that the prolonged treatment did not appear to interfere with this process. In studies of rats treated with high doses of p-chlorophenylalanine and phenylalanine (Prohaska & Wells, 1974) , the cerebral hexokinase and cytochrome c oxidase (EC 1.9.3.1) activities remained normal.
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Discussion
The amount of hepatic phenylalanine hydroxylase (judged by its activity in an optimally fortified assay system in vitro) appears to be the primary determinant of the capacity to metabolize phenylalanine in vivo: in adult rats, this was demonstrated with the aid ofthe inhibitor p-chlorophenylalanine (Guroff, 1969) ; in suckling rats, as we previously reported (McGee et al., 1972b) , cortisol-induced elevations of phenylalanine hydroxylase activity correlated quantitatively with increases in the rate constant of disappearance of a loading dose ofphenylalanine from plasma. However, major changes in rate constant altered by only about 30min the time-period during which the plasma phenylalanine concentration remained considerably above normal. Thus a near-complete inhibition of phenylalanine hydroxylase activity plus large doses of phenylalanine were expected to be necessary to obtain the degree of sustained hyperphenylalaninaemia aimed at in the present study. In our 6-day-old rats, 9-18,umol of p-chlorophenylalanine decreased the total potential phenylalanine hydroxylase activity (renal plus hepatic) of the organism from 188 to 34 units and the injection of as much as 26.umol of phenylalanine was then required for its concentration in plasma to be still considerably elevated 12h later. The best-documented neurological and behavioural abnormalities were reported for rats that had been given repeated doses ofonly 3pcmol ofp-chlorophenylalanine and 20umol of phenylalanine/lOg body wt. during infancy (Andersen & Guroff, 1972; Andersen et al., 1974) . We, however, found that an injection of these amounts did not inhibit the hepatic phenylalanine hydroxylase activity nor cause sustained hyperphenylalaninaemia. Thus the abnormalities observed might have been caused by factors other than the circulating phenylalanine unless, after prolonged treatment with even the low doses, there was a gradual accumulation of phenylalanine in plasma. It will of course be necessary to test whether these behavioural abnormalities in rats given low doses of p-chlorophenylalanine plus phenylalanine (Andersen & Guroff, 1972; Andersen et al., 1974) are different or less extensive than those which may be found inhyperphenylalaninaemic rats treated with the regimen described in Table 3 .
An almost threefold increase did occur in the course of prolonged treatment with the high doses of p-chlorophenylalanine plus phenylalanine (cf. Tables
Since the injection ofp-chlorophenylalanine did not completely abolish the phenylalanine hydroxylase activity, the administration of phenylalanine was expected to raise the concentration of tyrosine in plasma above the low values found after treatment with p-chlorophenylalanine alone. However, compared with the plasma of untreated ra'ts the increase (at 12 or 18 h after the last injection of phenylalanine)' was small or insignificant. The phenylalanine/tyrosine ratio, which was 0.27 in untreated rats, rose to about 4. This 15-fold difference in ratio compares favourably with that between normal human subjects and untreated phenylketonurics, with ratios of 0.8 and about 20 respectively (Lipton et al., 1967; Partington & Lewis, 1963) .
The inhibition of body and organ growth in the treated animals accords with observat'ions on, developing rats (Clarke &-Lowden, 1969) as well as with the lower brain size and head circumference of phenylketonurics (Knox, 1966) . Chronic hyperphenylalaninaemia did not alter the hepatic concentration of the three enzymes nor did it appear to interfere with the developmbntal formation of the six cerebral enzymes so far measured. Since in rats, cerebral development [N.B; myelination (Davison, 1971) ] is not 'accomplished' by the fourth postnatal week (Benjamins & McKhann, 1972) , it may be appropriate to test for cerebral abnormalities (biochemical, iltrastructural and behavioural) after an even moreprolonged treatment withp-chlorophenylalanine and phenylalanine. -The assumption that the regimen described in the present paper can produce a better animal model for phenylketonuria than those designed up to now, rests at present on the sustained hyperphenylalaninaemia achieved. Throughout a critical period of early postnatal development, at least 20-fold elevations of phentylalanime concentration in plasma persisted for the better part of each day. This' approaches the 20-30-fold diftfrence between untreated phenylketonuric and normal'! human subjectg' (Lipton et al., 1967; Partington & Lewis, 1963) .
